Kuzo, Nazar
Haen, Ekkehard
Ho, Dominic M.
Takeuchi, Hiroyoshi
Piras, Marianna
Eap, Chin-Bin
de Filippis, Renato
Homan, Philipp
Kane, John M.
Roy, Marc-André
Paulzen, Michael
Schoretsanitis, Georgios http://orcid.org/0000-0002-3851-4117
Funding for this research was provided by:
University of Zurich
Article History
Received: 6 July 2022
Accepted: 16 December 2022
First Online: 29 December 2022
Declarations
:
: Ekkehard Haen received speaker’s or consultancy fees from Servier, Novartis, and Janssen-Cilag. He is managing director of AGATE, a non-profit working group to improve drug safety and effectiveness in the treatment of psychiatric diseases. Hiroyoshi Takeuchi has grants from Daiichi Sankyo and Novartis Pharma; speaker’s fees from EA Pharma, Kyowa, Janssen, Lundbeck, Meiji Seika Pharma, Otsuka, Sumitomo Pharma, Takeda, and Yoshitomiyakuhin; and consultant fees from Janssen, Mitsubishi Tanabe Pharma, and Sumitomo Pharma. Chin-Bin Eap received honoraria for conferences or teaching CME courses from Forum pour la formation médicale, Janssen-Cilag, Lundbeck, Otsuka, Sandoz, Servier, Sunovion, Sysmex Suisse AG, Takeda, Vifor-Pharma and Zeller in the past 3 years. John M. Kane has been a consultant and/or advisor to or has received honoraria from Alkermes, Allergan, Boehringer Ingelheim, Bristol-Myers Squibb, Dainippon Sumitomo, IntraCellular Therapies, Janssen, Lundbeck, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Saladex, Sunovion, Takeda and Teva. He is a shareholder of LB Pharma, and The Vanguard Research Group. Michael Paulzen has received speaker’s fees from Neuraxpharm and Lundbeck. Marc-André Roy has received grants from Otsuka-Lundbeck Alliance, Janssen, Sunovion, AbbVie and Mylan. Georgios Schoretsanitis has served as a consultant for HLS Therapeutics and Thermo Fisher and has received speaker's fees from HLS Therapeutics. All other authors report no conflicts of interests.